Searchable abstracts of presentations at key conferences in endocrinology

ea0073aep552 | Pituitary and Neuroendocrinology | ECE2021

A complex case of refractory hypercalcaemia, end-stage diabetic nephropathy with pituitary mass and hypopituitarism– is there a unifying diagnosis?

Fennell David , Holland John A , Corkery Laura , Ludgate Stephen , McQuaid Siobhan

A 54-year-old female presented with one week of weakness, fatigue, headache, worsening constipation, and general malaise. Background history included long-standing type 1 diabetes (glutamic acid decarboxylase positive), on continuous subcutaneous insulin infusion, proliferative diabetic retinopathy, end-stage diabetic nephropathy on haemodialysis and subclinical hypothyroidism. Tertiary hyperparathyroidism was diagnosed (adjusted calcium 2.82 mmol/l, phosphate 1.42 mmol/l, par...

ea0070aep671 | Pituitary and Neuroendocrinology | ECE2020

To score or not to score? Is Ki-67 analysis worthwhile in pituitary neuroendocrine tumours?

Benjamin Loughrey Paul , Craig Stephanie , Herron Brian , Abdullahi Sidi Fatima , McQuaid Stephen , Kelly Paul , Humphries Matt , Parkes Eileen , McArt Darragh , Hunter Steven , Korbonits Marta , James Jacqueline

Pituitary neuroendocrine tumours (PitNETs) are heterogeneous and have limited biomarkers to predict their behaviour, thus making their prognostication difficult. Ki-67 is a protein expressed in active phases of the cell cycle and is one of the biomarkers utilized in routine assessment of PitNET tissue. Current European Society of Endocrinology recommendations advise that histopathological analysis of PitNETs should as a minimum include Ki-67 proliferation index and anterior pi...